BioCentury
ARTICLE | Clinical News

Metadoxine: Completed Phase II enrollment

November 11, 2013 8:00 AM UTC

Alcobra completed enrollment of 36 patients with predominantly inattentive ADHD in a double-blind, crossover, Israeli Phase II trial evaluating placebo and once-daily 700 and 1,400 mg oral MG01CI each...